BeOne Medicines AG

BeOne Medicines AG

ONC - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$40.84B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
BeOne Medicines AGBeOne Medicines AG27.8-13%6.80.2
$414.60

Target Price by Analysts

13.3% upsideBeOne Medicines AG Target Price DetailsTarget Price

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$40.84 Billion
Enterprise Value$36.96 Billion
Earnings per Share$33.8
Beta0.52
Outstanding Shares111,575,811

Return

Return on Equity12.67%ROE
Return on Assets7.15%
Return on Invested Capital13.78%

Valuation & Multiples

P/E Ratio27.82P/E Ratio
PEG18.39PEG
Price to Sales6.78Price to Sales
Price to Book Ratio7.96Price to Book Ratio
Enterprise Value to Revenue6.03
Enterprise Value to EBIT38
Enterprise Value to Net Income56
Total Debt to Enterprise0.03
Debt to Equity0.24Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
August 5, 2026
EPS Estimate
$1.63
Consensus analyst estimate
Revenue Estimate
$1.62 B
Consensus analyst estimate

Next Earnings Call

Expected Date
November 5, 2026
EPS Estimate
$1.89
Consensus analyst estimate
Revenue Estimate
$1.75 B
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.0000▼ 72.81%
Total Calls-▼ 100.00%
Total Puts-▼ 100.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %0.15%▼ 31.19%
Total Invested$58.62M▼ 99.41%
Investors Holding40▼ 256.00%

About BeiGene Ltd

12,000 employees
CEO: John Oyler

BeOne Medicines AG, an oncology-focused enterprise headquartered in Basel, Switzerland, was established in 2010. This company is actively involved in the exploration and advancement of a diverse range of therapeutic solutions for cancer ...

BeOne Medicines AG Insider Information FAQ

Stockcircle shows 44 open-market insider sales for BeOne Medicines AG in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.